

## ORIGINAL RESEARCH

## A Cluster Analysis of Initial Primary Care Orders for Patients with Acute Low Back Pain

Christopher T. Joyce, PT, DPT, PhD, Eric J. Roseen, DC, MSc, Clair N. Smith, MS, Charity G. Patterson, PhD, Christine M. McDonough, PhD, PT, Emily Hurstak, MD, MPH, Natalia E. Morone, MD, MS, Jason Beneciuk, PT, DPT, PhD, MPH, Joel M. Stevans, DC, PhD, Anthony Delitto, PT, PhD, and Robert B. Saper, MD, MPH

**Purpose:** Primary care physicians (PCPs) often face a complex intersection of patient expectations, evidence, and policy that influences their care recommendations for acute low back pain (aLBP). The purpose of this study was to elucidate patterns of PCP orders for patients with aLBP, identify the most common patterns, and describe patient clinical and demographic characteristics associated with patterns of aLBP care.

**Methods:** This prospective cohort study included 9574 aLBP patients presenting to 1 of 77 primary care practices in 4 geographic locations in the United States. We performed a cluster analysis of PCP orders extracted from electronic health records within the first 21 days of an initial visit for aLBP.

**Results:** 1401 (15%) patients did not receive a PCP order related to back pain within the first 21 days of their initial visit. These patients predominantly had aLBP without leg pain, less back-related disability, and were at low-risk for persistent disability. Of the remaining 8146 patients, we found 4 distinct order patterns: combined nonpharmacologic and first-line medication (44%); second-line medication (39%); imaging (10%); and specialty referral (7%). Among all patients, 29% received solely 1 order from their PCP. PCPs more often combined different guideline concordant and discordant orders. Patients with higher self-reported disability and psychological distress were more likely to receive guideline discordant care.

**Conclusion:** Guideline discordant orders such as steroids and NSAIDs are often combined with guideline recommended orders such as physical therapy. Further defining patient, clinician, and health care setting characteristics associated with discordant care would inform targeted efforts for deimplementation initiatives. (J Am Board Fam Med 2023;00:000–000.)

**Keywords:** Acute Pain, Low Back Pain, Musculoskeletal Pain, Primary Health Care, Prospective Studies

## Introduction

Chronic low back pain (cLBP) is a leading cause of disability and health care utilization.<sup>1,2</sup> Effective

initial management of acute low back pain (aLBP) may prevent cLBP<sup>3,4</sup> and downstream health care costs.<sup>5,6</sup> Primary care physicians (PCPs) are often the initial clinician for patients with aLBP;<sup>7</sup> back pain is the second most common symptomatic reason for a primary care visit.<sup>8</sup> Thus, PCPs are uniquely positioned to

This article was externally peer reviewed.

Submitted 28 March 2023; revised 31 May 2023; 13 June 2023; accepted 20 June 2023.

This is the Ahead of Print version of the article.

From the School of Physical Therapy, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA (CTJ); Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, MA (EJR, EH, NEM); School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, PA (CNS, CGP, CMM, JMS, AD); Department of Physical Therapy, College of Public Health and Health Professions, University of Florida, Gainesville, FL, United States (JB); Clinical Research Center, Brooks Rehabilitation, Jacksonville, FL, United States (JB); Department of Wellness and Preventive Medicine, Cleveland Clinic, Cleveland, OH, USA (RBS).

**Funding:** The TARGET Trial and Inception Cohort were funded by the Patient Centered Outcomes Research Institute (PCORI contract # NCT02647658). ClinicalTrials.gov Identifier: NCT02647658.

**Conflict of interest:** The authors have no conflicts of interest to declare.

**Corresponding author:** Christopher T. Joyce, PT, DPT, PhD, School of Physical Therapy, Massachusetts College of Pharmacy and Health Sciences, 10 Lincoln Square, Worcester, MA 01608 (E-mail: Christopher.Joyce@mcpshs.edu).

influence the trajectory of patients with aLBP in terms of recovery and subsequent health care utilization.

Clinical practice guidelines by the American College of Physicians recommend nonpharmacologic approaches such as massage and spinal manipulation for initial management for aLBP (recommendation strength: strong).<sup>9</sup> Medications such as nonsteroidal anti-inflammatories (NSAIDs) and muscle relaxants are considered a first-line treatment for aLBP only if the patient expresses preference for a medication (recommendation strength: strong).<sup>9,10</sup> Pharmacologic treatments such as opioids are associated with a greater risk profile and are not recommended for aLBP. In the absence of progressive neurologic symptoms or other red flags, radiographic and magnetic resonance imaging should be delayed until after a trial of nonpharmacologic and/or first-line pharmacologic treatment. While there is no guideline recommendation for when to refer to a medical specialist, this referral is often associated with utilization of invasive procedures (eg, epidural injections) that are not recommended.<sup>11</sup>

Although the practice patterns of PCPs for low back pain have been described previously,<sup>11–13</sup> few studies capture the complexity of PCP orders relative to current clinical practice guidelines. More commonly, previous literature focuses on single interventions rather than how treatments are combined in real-world practice. For example, imaging,<sup>14,15</sup> opioid prescribing,<sup>16</sup> physical therapy (PT),<sup>17</sup> and other nonpharmacologic treatments<sup>18</sup> have been compared against themselves in primary care settings using claims databases. However, claims analyses typically examine new episodes of care which are likely a heterogeneous group of acute, subacute, and chronic back pain. Moreover, claims data does not provide a comprehensive view of PCP recommendations. PCPs may recommend several concurrent treatments (eg, opioid prescription and order for PT), diagnostic tests, or consultations (eg, a radiograph and referral to a specialist) and the patient self-selects the services they use. Last, claims data provide limited insight on patient-related clinical characteristics that may be influencing PCP decision making. Given the high prevalence of back pain in primary care settings, there is a need to describe the combinations

of treatments PCPs recommend to patients with aLBP.

Recently, in a large sample of patients with aLBP initially seen in primary care, we found associations between the amount of guideline discordant treatments (eg, opioids) or procedures (eg, imaging) provided and the risk of developing cLBP.<sup>19</sup> However, we did not explore combinations of orders that may be both guideline concordant and discordant simultaneously. Clarifying the degree to which nonconcordant treatments are recommended as the sole intervention or in combination with other treatments is important to understanding the degree to which current clinical practice guidelines have been implemented in routine primary care practice. Moreover, identifying any distinguishing characteristics in populations receiving certain forms of care will guide implementation efforts to improve care. The aims of this study were to: 1) describe guideline concordant and discordant health care orders initiated by PCPs for patients with aLBP, 2) identify similar patterns of orders, and 3) describe patient clinical and demographic characteristics associated with order patterns.

## Methods

### Study Design

The Targeted Interventions to Prevent Chronic Low Back Pain in High-Risk Patients (TARGET) protocol and primary results articles have been published elsewhere.<sup>19–21</sup> Briefly, 9547 aLBP patients presenting to 1 of 77 primary care practices in 4 geographic locations (Baltimore, MD; Boston, MA; Pittsburgh, PA; Salt Lake City, UT) were screened using the STarT Back Tool<sup>22</sup> and stratified as being at low, moderate, or high risk of developing chronic low back pain. Regardless of risk stratification, all patients were followed over the next twelve months as part of the inception cohort study. High-risk patients (n = 2300) were additionally enrolled in a pragmatic, multi-site, randomized controlled trial that compared usual care to referral to a stratified approach to care using psychologically informed physical therapy (ie, PT that is combined with cognitive behavioral strategies). Patients were enrolled between May 2016 and June 2018. Four institutional review boards approved the trial. The current study included all patients enrolled in the trial and cohort.

### Sample

Patients were eligible for enrollment if they were 18 years of age or older and presented to the clinic with a primary complaint of acute axial LBP or LBP with associated leg pain as determined by ICD-9 or ICD-10-CM diagnosis codes. Patients with the signs or symptoms associated with serious pathology (eg, vertebral fracture, cancer) were excluded. To ensure acuity of low back pain, a 2-item acute/chronic LBP screening questionnaire was created by adapting the National Institute of Health Research Standards definition for chronic LBP.<sup>23</sup> Patients were asked: (1) how long has your low back pain interfered with your ability to do regular daily activities, and, (2) in the last 6 months, how often has low back pain interfered with your ability to do regular activities. If the patient answered “more than 3 months” for the first question, and “half or more than half the days” for the second question, they were considered chronic and excluded from the study.

### Data Collection

Primary care orders and patient characteristics were extracted from their respective field in the patient’s electronic medical record. Clinical characteristics were extracted from the electronic medical record except for disability and risk stratification which were collected at index visit.

### Primary Care Orders

Initial primary care orders were defined as occurring within the first 21 days of an index visit. Orders were categorized into 5 main groups, described below. A detailed breakdown of orders (eg, medications included as steroids, pain management clinicians) is provided in Appendix A.

### Non-Pharmacologic

Behavioral health (eg, psychology, psychiatry), chiropractic, mind-body therapies (eg, acupuncture, massage), pain management (eg, pain clinic, physical medicine and rehabilitation), PT, social work, wellness coaching.

*First-Line Pharmacologic.* Acetaminophen, muscle relaxant, NSAID, and topical NSAID.

*Second-Line Pharmacologic.* Antidepressant, benzodiazepine, opioid, steroid.

*Specialty Referral.* Neurology, spine/orthopedic surgery.

*Imaging.* Computed tomography (CT), magnetic resonance imaging (MRI), or plain radiography (radiograph).

### Patient and Clinical Characteristics

Patient and clinical characteristics are described as follows:

#### Patient Characteristics

Demographics, health insurance (commercial, Medicare, Medicaid and self-pay/other), smoking status (yes/no), body mass index, geographic location of the clinics.

#### Clinical Characteristics

Back pain diagnosis (axial back pain vs back and leg pain), self-reported LBP functional disability, and risk stratification. Back pain diagnosis was identified via ICD-9 or ICD-10 diagnostic codes present at the index encounter. Self-reported LBP functional disability was measured using the Oswestry Disability Index (ODI),<sup>24</sup> a self-report scale ranging from 0 to 100 with lower scores indicating less disability. Risk stratification was assessed using the Keele STarT Back Tool<sup>22</sup> which assigns a risk of developing cLBP based on patient response to 4 symptom-based and 5 psychological-based items. Scores range from 0 to 9. Patients are characterized as low-risk (total score  $\leq 3$ ), medium-risk (total score  $\geq 4$  and psychological score  $\leq 3$ ), or high risk (total score  $\geq 4$  and psychological score  $\geq 4$ ). <https://startback.hfac.keele.ac.uk/training/resources/startback-online/>.

### Analysis

Individual PCP orders and common combinations of orders relevant to low back pain guidelines were examined and are described as frequencies.

Next, a cluster analysis was used to identify distinct groups of patients based on patterns or similarities of particular variables of interest. In this analysis, different types of PCP orders were the variables used to cluster patients. When performing a cluster analysis on a large data set with dichotomous variables (ie, received an order or did not), halving the data into a “training” set and “validation” set can guide the interpretation of the clusters.<sup>25</sup> The “training” set is first analyzed and used to independently determine the number of clusters. The “validation” set is then analyzed using the same clustering method and number of clusters

from the training set. In this analysis, comparisons of order frequencies as well as clinical and demographic data of the participants in each cluster were examined to evaluate similarity between the clusters from each data set.

Patients who received no orders within the first 21 days were extracted as a separate group leaving those who had at least 1 early primary care order within 21 days of index visit included in the cluster analysis. These patients were split into 2 equal samples using simple random sampling. One half of the data, the “training” dataset, was used to determine the number of clusters. The clustering method was average linkage hierarchical agglomerative clustering and the Jaccard index was used as a measure of distance between patients.<sup>25</sup> The research team reviewed the different models of clusters with the aim of identifying the most parsimonious model with robust numbers per cluster and distinct order patterns among clusters. Once the number of clusters was selected, the other half of the data were used to validate the original clusters.

Clusters were named according to the predominant category (eg, Non-Pharmacological & first-Line Pharmacological) of PCP orders within the cluster. Categories of PCP orders are presented as frequencies within each cluster. The categories were broken down into specific types of orders within each cluster. In addition, common combinations of individual orders in the clusters are described as frequencies. Finally, we compared patient and clinical characteristics among clusters in the training and validation sets to determine if characteristics were associated with clusters. Patient, clinician, and clinical characteristics within each cluster are described as means or frequencies. Analysis was performed in SAS version 9.4.

## Results

Of the full sample (9574), 1401 (15%) patients received no PCP order within the first 21 days (Table 1). These patients were predominantly stratified as low-risk (60%), had axial back pain only (89%), and low disability (mean ODI = 23). In the remaining 8146 patients, PCPs solely placed 1 order in 29% of initial visits. When comparing solely nonpharmacologic versus pharmacologic orders, 8% of patients received only nonpharmacologic orders whereas 33% received only

**Table 1. Primary Care Physician Orders for 9574 Patients with Acute Low Back Pain Within the First 21 Days of Initial Encounter**

|  | Total (n = 9547) |
|--|------------------|
| PCP Orders   |                  |
| No order   | 1,401 (15%)      |
| One order  | 2,780 (29%)      |
| Two orders   | 2,743 (29%)      |
| Three orders   | 1,702 (18%)      |
| Non-pharmacologic only   | 729 (8%)         |
| Pharmacologic only   | 3,124 (33%)      |
| Multiple pharmacologic   | 3,400 (36%)      |
| Concordant with Guidelines *                                     |                  |
| Non-pharmacologic  | 3,390 (36%)      |
| Physical therapy   | 3,321 (34%)      |
| Physical therapy + NSAID   | 1,057 (11%)      |
| Physical therapy + Muscle relaxant                               | 1,247 (13%)      |
| Partially Concordant with Guidelines*                            |                  |
| Non-pharmacologic + 2 <sup>nd</sup> Line Pharm                   | 1,267 (13%)      |
| Physical therapy + Steroid                                       | 790 (8%)         |
| Physical therapy + Opioid  | 502 (5%)         |
| Physical therapy + Radiograph                                    | 721 (8%)         |
| Non-concordant with Guidelines*                                  |                  |
| Opioid   | 1,706 (18%)      |
| Opioid + Muscle relaxant   | 742 (8%)         |
| Opioid + NSAID   | 397 (4%)         |
| Steroid  | 2,356 (25%)      |
| Steroid + Muscle relaxant  | 1,181 (12%)      |
| Steroid + NSAID  | 473 (5%)         |
| MRI or Radiograph  | 2,238 (23%)      |
| Solely 2 <sup>nd</sup> Line Pharmacologic, Imaging, or Specialty | 1,306 (14%)      |

*Notes.* All values are n (%) where n is the number of patients who received the order.

\*Rows are not mutually exclusive (i.e., patients who received physical therapy + NSAID are also included in the physical therapy row) unless otherwise stated.

*Abbreviations:* NSAID, non-steroidal anti-inflammatory drugs; PCP, primary care physicians.

pharmacologic (first or second line) orders. There was wide variability in the orders made by PCPs and their concordance with the guidelines. When considering guideline concordant care, 34% of patients received an order for PT and, of them, 11% got an additional NSAID order and 13% received an order for a muscle relaxant. When considering orders that were partially concordant with the guidelines, 13% of patients received a combination of a concordant non-pharmacologic order with a nonconcordant second-line pharmacologic order. However, 14% of patients received solely nonconcordant second-line pharmacologic (8%), imaging (4%), or specialty (2%) orders.



**Table 2. Cluster Analysis of Primary Care Physician Orders Within the First 21 Days from Initial Visit in 4073 Patients with Acute Low Back Pain**

|                                    | Non-Pharm & 1 <sup>st</sup> Line Pharm<br>N = 1810 | 2 <sup>nd</sup> Line Pharm<br>N = 1470 | Imaging<br>N = 525 | Specialty<br>N = 268 |
|------------------------------------|--|--|--------------------|----------------------|
| Non-Pharmacologic                  | 962 (53)   | 494 (34)                               | 209 (40)           | 42 (16)              |
| 1 <sup>st</sup> Line Pharmacologic | 1,430 (79)   | 889 (60)                               | 0                  | 116 (43)             |
| 2 <sup>nd</sup> Line Pharmacologic | 0  | 1,470 (100)                            | 206 (39)           | 154 (57)             |
| Specialty                          | 39 (2)   | 0                                      | 14 (3)             | 268 (100)            |
| Imaging                            | 264 (15)   | 255 (17)                               | 525 (100)          | 88 (33)              |

Notes. All values are n (%) where n is the number of patients within the cluster who received that order.

The training cluster data set (n = 4073) yielded 4 different models ranging from 2 to 5 clusters. The 4-cluster model was selected based on distinctiveness of physician orders (Table 2). This model was used in the validation data set and compared against the training data set to assess and confirm similarity (Appendix B). The proportion of order frequency as well as patient demographic and clinical characteristics were evaluated to determine consistency between the 2 data sets. The 4 clusters were: 1) Non-Pharm and first-Line Pharm (44%); 2) second-Line Pharm (36%); 3) Imaging (13%); and 4) Specialty (7%).

The Non-Pharm and first-Line Pharm cluster (n = 1810) was the youngest (mean age = 48) and had the

largest proportion of Black patients (22%) of the clusters. They mostly had axial back pain (81%) and less disability (mean ODI = 31). In this cluster, 39% and 20% of patients received solely first-line pharmacologic or nonpharmacologic orders, respectively (Table 3). The most common combination was a nonpharmacologic order with a first-line pharmacologic order (25%). Frequent orders in this cluster were PT (n = 934; 52%), muscle relaxants (n = 940; 52%), and NSAIDs (n = 933; 52%) (Table 4).

The second-Line Pharm cluster (n = 1470) had the highest proportion of white (88%), privately insured (53%) patients, and the highest disability (mean ODI = 40) (Table 5). In this cluster, 71% of

**Table 3. Common Combinations of Primary Care Physician Orders Within the First 21 Days from Initial Visit in 4073 Patients with Acute Low Back Pain**

| Order Combinations   | Non Pharm & 1 <sup>st</sup> Line Pharm | 2 <sup>nd</sup> Line Pharm | Imaging  | Specialty |
|--|--|----------------------------|----------|-----------|
| 1 <sup>st</sup> Line Pharm Only  | 697 (39)                               |                            |          |           |
| 1 <sup>st</sup> Line Pharm with Non-Pharm                                | 453 (25)                               |                            |          |           |
| Non-Pharm Only   | 361 (20)                               |                            |          |           |
| 2 <sup>nd</sup> Line Pharm with 1 <sup>st</sup> Line Pharm               |  | 419 (29)                   |          |           |
| 2 <sup>nd</sup> Line Pharm Only  |  | 401 (27)                   |          |           |
| 2 <sup>nd</sup> Line Pharm with 1 <sup>st</sup> Line Pharm and Non-Pharm |  | 215 (15)                   |          |           |
| 2 <sup>nd</sup> Line Pharm with Non-Pharm                                |  | 180 (12)                   |          |           |
| 2 <sup>nd</sup> Line Pharm with 1 <sup>st</sup> Line Pharm and Imaging   |  | 156 (11)                   |          |           |
| Imaging Only   |  |                            | 198 (38) |           |
| Imaging with 2 <sup>nd</sup> Line Pharm                                  |  |                            | 118 (22) |           |
| Imaging with Non-Pharm   |  |                            | 107 (20) |           |
| Imaging with 2 <sup>nd</sup> Line Pharm and Non-Pharm                    |  |                            | 88 (17)  |           |
| Specialty Only   |  |                            |          | 55 (21)   |
| Specialty with 1 <sup>st</sup> Line Pharm and 2 <sup>nd</sup> Line Pharm |  |                            |          | 40 (15)   |
| Specialty with 2 <sup>nd</sup> Line Pharm                                |  |                            |          | 35 (13)   |
| Specialty with 1 <sup>st</sup> Line Pharm                                |  |                            |          | 28 (10)   |

Notes. All values are n (%) where n is the number of patients within the cluster who received that type of order or order combination. Orders or combinations of orders less frequent than 10% are excluded.

**Table 4. Specific Primary Care Physician Orders Within the First 21 Days from Initial Visit in 4073 Patients with Acute Low Back Pain**

| Orders                             | Clusters                               |                            |          |           |
|------------------------------------|--|----------------------------|----------|-----------|
|                                    | Non-Pharm & 1 <sup>st</sup> Line Pharm | 2 <sup>nd</sup> Line Pharm | Imaging  | Specialty |
| Non-Pharmacologic                  |  |                            |          |           |
| Physical Therapy                   | 934 (52)                               | 464 (32)                   | 200 (38) | 42 (16)   |
| Other*                             | 24 (1)                                 | 16 (1)                     | 5 (1)    | 1 (0)     |
| 1 <sup>st</sup> Line Pharmacologic |  |                            |          |           |
| Acetaminophen                      | 55 (3)                                 | 11 (1)                     | 0        | 4 (1)     |
| Muscle relaxant                    | 940 (52)                               | 747 (51)                   | 0        | 75 (28)   |
| NSAID                              | 933 (52)                               | 360 (24)                   | 0        | 69 (26)   |
| 2 <sup>nd</sup> Line Pharmacologic |  |                            |          |           |
| Benzodiazepine                     | 0                                      | 96 (7)                     | 17 (3)   | 11 (4)    |
| Opioid                             | 0                                      | 655 (45)                   | 93 (18)  | 94 (35)   |
| Steroid                            | 0                                      | 913 (62)                   | 12 (2)   | 91 (34)   |
| Antidepressant                     | 0                                      | 144 (10)                   | 11 (2)   | 15 (6)    |
| Imaging                            |  |                            |          |           |
| MRI or CT Scan                     | 22 (1)                                 | 55 (4)                     | 98 (19)  | 43 (16)   |
| Radiography                        | 248 (14)                               | 210 (14)                   | 434 (83) | 51 (19)   |
| Specialty                          |  |                            |          |           |
| Neurology or PM&R                  | 14 (1)                                 | 0                          | 3 (1)    | 118 (44)  |
| Spine surgery                      | 25 (1)                                 | 0                          | 12 (2)   | 161 (60)  |

Notes. All values are n (%) where n is the number of patients who received the order within that cluster.

\*Includes chiropractic, behavioral health, coaching, mind-body therapies, pain management, social work.

Abbreviations: NSAID, non-steroidal anti-inflammatory drugs; MRI, magnetic resonance imaging; CT, computed tomography; PM&R, physical medicine and rehabilitation.

patients received 1 (27%) or more than 1 (44%) second- and first-line pharmacologic orders. The most frequent orders in this cluster were steroids (n = 913; 62%), muscle relaxants (n = 747; 51%), and opioids (n = 655; 45%).

The Imaging cluster (n = 525) was the oldest (mean age = 56) and had the highest proportion of females (62%). Imaging orders were predominantly for plain radiographs (n = 434; 83%) and were combined with second-line pharm (n = 118; 22%) or nonpharm (n = 107; 20%) orders. The Specialty cluster was comparatively small (n = 268) but contained the largest proportion of patients who were stratified as high risk (38%), had back and leg pain (41%) and had pain greater than 3 months (23%).

## Discussion

We determined PCP patterns of care for 9574 adults with aLBP presenting to 77 primary care clinics in 4 geographic regions. We found that PCPs often combined multiple orders rather than a single order, but that there was wide variation in the order type and combination. This frequently

resulted in PCP orders being partially concordant with current guidelines (ie, referring to a recommended treatment) while also prescribing a second-line or nonrecommended medication or imaging for initial care of aLBP.

Our findings have implications for trials that have “usual care” comparators.<sup>26</sup> Without fully understanding what is included in usual care, estimates for comparative treatment effects may be confounded. This is, nonetheless, the reality of low back primary pain care where patient complexity is common and there are multiple choices for evidence-based treatments. And, while the recommendations from the guidelines are “strong,” the quality of the evidence for the different treatments varies (eg, low quality evidence for massage, spinal manipulation and acupuncture). Various factors may influence PCP orders such as patient comorbidities, patient preferences, availability of resources, long wait-lists for nonpharmacologic clinicians, payer types, and clinician beliefs about the evidence base for the guidelines.<sup>27</sup> We identified some distinguishing patient-characteristics that may explain some of the variation in PCP orders.

**Table 5. Characteristics of 1401 Patients with Acute Low Back Pain Who Did Not Receive a Physician Order and 4073 Patients Clustered by Predominant Physician Orders Within 21 Days of Initial Visit**

|                                      | No Order<br>N = 1401 | Non-Pharm &<br>1 <sup>st</sup> -Line Pharm<br>N = 1810 | 2 <sup>nd</sup> -Line Pharm<br>N = 1470 | Imaging<br>N = 525 | Specialty<br>N = 268 | Total<br>N = 4073 |
|--------------------------------------|----------------------|--|---|--------------------|----------------------|-------------------|
| Age, mean (SD)                       | 52 (18)              | 48 (17)  | 50 (16)                                 | 56 (18)            | 53 (16)              | 50 (17)           |
| Women                                | 826 (59)             | 1063 (59)  | 818 (56)                                | 323 (62)           | 137 (51)             | 2341 (57)         |
| Race                                 |                      |  |   |                    |                      |                   |
| White                                | 1113 (80)            | 1250 (69)  | 1289 (88)                               | 454 (86)           | 210 (79)             | 3203 (79)         |
| Black                                | 190 (14)             | 389 (22)   | 113 (8)                                 | 45 (9)             | 37 (14)              | 584 (14)          |
| Missing/Other                        | 96 (6)               | 171 (9)  | 68 (4)                                  | 26 (5)             | 19 (7)               | 284 (7)           |
| Ethnicity                            |                      |  |   |                    |                      |                   |
| Hispanic                             | 64 (5)               | 102 (6)  | 43 (3)                                  | 15 (3)             | 15 (6)               | 175 (4)           |
| Non-Hispanic                         | 1291 (92)            | 1658 (92)  | 1397 (95)                               | 499 (95)           | 242 (91)             | 3796 (93)         |
| Missing                              | 44 (3)               | 50 (2)   | 30 (2)                                  | 11 (2)             | 9 (3)                | 157 (4)           |
| Location                             |                      |  |   |                    |                      |                   |
| Baltimore, MD                        | 243 (17)             | 395 (22)   | 161 (11)                                | 62 (12)            | 56 (21)              | 675 (17)          |
| Boston, MA                           | 165 (12)             | 332 (18)   | 50 (3)                                  | 12 (2)             | 35 (13)              | 429 (11)          |
| Pittsburgh, PA                       | 713 (51)             | 736 (41)   | 852 (58)                                | 370 (70)           | 124 (47)             | 2082 (51)         |
| Salt Lake City, UT                   | 278 (20)             | 347 (19)   | 406 (28)                                | 81 (15)            | 53 (20)              | 887 (22)          |
| Insurance                            |                      |  |   |                    |                      |                   |
| Medicare                             | 355 (25)             | 295 (16)   | 291 (20)                                | 170 (32)           | 58 (22)              | 814 (20)          |
| Medicaid                             | 122 (9)              | 188 (10)   | 132 (9)                                 | 37 (7)             | 24 (9)               | 381 (9)           |
| Private                              | 698 (50)             | 885 (49)   | 784 (53)                                | 228 (43)           | 123 (46)             | 2020 (50)         |
| Missing/Other                        | 224 (16)             | 442 (25)   | 263 (18)                                | 90 (18)            | 61 (23)              | 856 (21)          |
| Current Smoker                       |                      |  |   |                    |                      |                   |
| No                                   | 915 (68)             | 1140 (63)  | 956 (65)                                | 391 (74)           | 156 (59)             | 2643 (65)         |
| Yes                                  | 115 (8)              | 179 (10)   | 227 (15)                                | 51 (10)            | 45 (17)              | 502 (12)          |
| Missing                              | 333 (24)             | 491 (27)   | 287 (20)                                | 83 (16)            | 65 (24)              | 926 (23)          |
| Body Mass Index mean (SD)            | 29 (6)               | 32 (9)   | 32 (8)                                  | 30 (8)             | 32 (8)               | 32 (8)            |
| STarT Back                           |                      |  |   |                    |                      |                   |
| Low                                  | 834 (60)             | 686 (38)   | 359 (24)                                | 188 (36)           | 59 (22)              | 1292 (32)         |
| Medium                               | 382 (27)             | 683 (38)   | 687 (47)                                | 196 (37)           | 105 (39)             | 1671 (41)         |
| High                                 | 183 (13)             | 441 (24)   | 424 (29)                                | 141 (27)           | 102 (39)             | 1108 (27)         |
| Baseline ODI, mean (SD) <sup>±</sup> | 23 (17)              | 31 (18)  | 40 (19)                                 | 31 (20)            | 40 (21)              | 35 (19)           |
| Axial back pain                      | 1210 (86)            | 1472 (81)  | 999 (68)                                | 356 (68)           | 156 (59)             | 2983 (73)         |
| Back and leg pain                    | 189 (14)             | 338 (19)   | 471 (32)                                | 169 (32)           | 110 (41)             | 1088 (27)         |
| Back pain >3 months                  | 219 (16)             | 239 (13)   | 192 (13)                                | 88 (17)            | 60 (23)              | 579 (14)          |

Notes. \*All values are n (%) of patients within that cluster unless otherwise noted.

<sup>±</sup>ODI: Oswestry Disability Index; 0–100 with lower scores indicating less disability.

Abbreviations: SD, standard deviation.

### Low-Moderate Risk Patterns

PCPs appeared to recognize and provide guideline concordant care to patients who had low disability and were stratified by the STarT Back score as low-risk. A common combination for patients with low to moderate risk of developing cLBP was a non-pharmacologic order with a first-line medication. This practice is congruent with guidance that recommends nonpharmacologic treatments first and, if requested by the patient, in combination with an NSAID or muscle relaxant.

### High-Risk Patterns

Patients who were stratified as high risk of developing disability and had longer duration of symptoms tended to be in the clusters that received orders associated with greater risk or cost such as opioids, steroids, imaging orders, and to a lesser extent, specialty referral. It is conceivable that PCPs seeing patients with more severe presentation recommended invasive or aggressive treatments that were not guideline concordant. Thus, guideline implementation or deimplementation interventions targeting clinicians

may need to focus on this patient subgroup. However, it is also conceivable that patients who self-report higher disability and psychological distress perceive a stronger need for advanced care and place pressure on clinicians to receive it.<sup>28–31</sup> This pattern of patient presentation has been described in the emergency medicine department where patients with nonspecific low back pain receive high-rates of imaging and opioid medications.<sup>32–34</sup> However, clinical trials do not support the premise that pain medications are more effective among patients with severely intense or disabling aLBP compared with nonpharmacologic approaches.<sup>35,36</sup> Our previous study suggests that opioids and nonopioid medications are associated with a higher transition to cLBP.<sup>19</sup>

The STarT Back tool stratifies patients into high-risk if they respond positively to statements about pain related psychological distress as these patients have been shown to have worse outcomes.<sup>22</sup> With this in mind, using integrated behavioral health or referring to other clinician (eg, rehabilitation) who can help patients process and cope with their pain may be more useful than medications and referrals. We say this while acknowledging that in the embedded trial (the TARGET trial) psychologically informed physical therapy did not improve outcomes among high-risk patients.<sup>20</sup> Yet, a program evaluation looking at implementation at 1 of the sites found implementation was challenging at multiple levels – screening in primary care, PCP referrals, scheduling visits, and attendance for psychologically informed physical therapy.<sup>37</sup> It may be that pain medication prescribing is common because it is convenient, routine, and has established systems for payment or coverage.<sup>38</sup> Previous work suggests that PCPs may select more aggressive care such as pain medication due to pressure from patients to receive immediate pain relief, concerns of patient dissatisfaction, and fear of litigation from patients.<sup>39</sup> Indeed, public health campaigns lead by clinicians to educate patients about the risks of overdiagnosing and overtreating LBP have been initiated in primary care and, while still in infancy, have faced resistance from patients.<sup>40</sup> The continued variability in practice and the persistence of guideline discordant care warrants research into implementation at multiple levels.

Our study has several limitations. Embedded within this observational cohort was a randomized trial on a PT intervention. Thus, nonpharmacologic

orders, particularly PT, may have been inflated and our findings may not be generalizable to other systems that do not have strongly integrated PT care options. Low order rates of non-PT nonpharmacologic approaches may not be captured in orders (eg, clinician recommendations for yoga, mindfulness based stress reduction occurring outside the medical system). Second, our medication orders were not linked to ICD-9 or ICD-10 in the electronic health record systems. Therefore, it is possible that certain orders such as antidepressant medications were related to other patient conditions. Our data cannot provide an explanatory model for why certain guideline discordant orders may have been chosen based on patient comorbidities (eg, imaging in patients with osteoporosis or history of malignancy). Last, a cluster analysis is helpful for identifying homogeneous groups of people based on a variable or variables of interest (in our case PCP orders). Similarities between generated clusters across other patient level variables suggests that there is not absolute distinction between who receives which PCP orders.

## Conclusion

Primary care physicians navigate a complex interaction between policy guidelines, patient preference, and resource availability when treating aLBP. Future research that measures clinical effectiveness and downstream utilization of guideline based combinations of treatments may be more pragmatic. In addition, implementation efforts targeted at patients and clinicians to increase use of nonpharmacologic treatment and prevent discordant care remains warranted.

---

The authors acknowledge the TARGET trial team.

To see this article online, please go to: <http://jabfm.org/content/00/00/000.full>.

## References

1. Mokdad AH, Ballestros K, Echko M, et al. The state of US health, 1990–2016. *JAMA* 2018;319:1444.
2. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1545–602.
3. Foster NE, Anema JR, Cherkin D, Lancet Low Back Pain Series Working Group, et al. Prevention



- and treatment of low back pain: evidence, challenges, and promising directions. *Lancet* 2018; 391:2368–83.
4. De Campos TF, Maher CG, Fuller JT, Steffens D, Attwell S, Hancock MJ. Prevention strategies to reduce future impact of low back pain: a systematic review and meta-analysis. *Br J Sports Med* 2021;55: 468–76.
  5. Hon S, Ritter R, Allen DD. Cost-effectiveness and outcomes of direct access to physical therapy for musculoskeletal disorders compared to physician-first access in the United States: systematic review and meta-analysis. *Phys Ther* 2021;101:1–11.
  6. Kim LH, Vail D, Azad TD, et al. Expenditures and health care utilization among adults with newly diagnosed lowback and lower extremity pain. *JAMA Netw Open* 2019;2:e193676–12.
  7. Kosloff TM, Elton D, Shulman SA, Clarke JL, Skoufalos A, Solis A. Conservative spine care: opportunities to improve the quality and value of care. *Popul Health Manag* 2013;16:390–6.
  8. Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. *Can Fam Physician* 2018;64:832–40.
  9. Qaseem A, Wilt TJ, McLean RM, Clinical Guidelines Committee of the American College of Physicians, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2017;166:514–30.
  10. Wong AY, Karppinen J, Samartzis D. Low back pain in older adults: risk factors, management options and future directions. *Scoliosis Spinal Disord* 2017;12:14.
  11. Stewart WF, Yan X, Boscarino JA, et al. Patterns of health care utilization for low back pain. *J Pain Res* 2015;8:523–35.
  12. Dietrich EJ, Leroux T, Santiago CF, Helgeson MD, Richard P, Koehlmoos TP. Assessing practice pattern differences in the treatment of acute low back pain in the United States Military Health System 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1103 Clinical Sciences. *BMC Health Serv Res* 2018;18:720–6.
  13. Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. *Spine J* 2011;11:622–32.
  14. Graves JM, Fulton-Kehoe D, Jarvik JG, Franklin GM. Early imaging for acute low back pain: one-year health and disability outcomes among Washington state workers. *Spine (Phila Pa 1976)* 2012;37:1617–27.
  15. Webster BS, Cifuentes M. Relationship of early magnetic resonance imaging for work-related acute low back pain with disability and medical utilization outcomes. *J Occup Environ Med* 2010;52:900–7.
  16. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. *Spine (Phila Pa 1976)* 2007;32:2127–32.
  17. Fritz JM, Kim M, Magel JS, Asche CV. Cost-effectiveness of primary care management with or without early physical therapy for acute low back pain. *Spine (Phila Pa 1976)* 2017;42:285–90.
  18. Kazis LE, Ameli O, Rothendler J, et al. Observational retrospective study of the association of initial health-care provider for new-onset low back pain with early and long-term opioid use. *BMJ Open* 2019;9: e028633–9.
  19. Stevans JM, Delitto A, Khoja SS, et al. Risk factors associated with transition from acute to chronic low back pain in US patients seeking primary care. *JAMA Netw open* 2021;4:e2037371.
  20. Delitto A, Patterson CG, Stevans JM, et al. Stratified care to prevent chronic low back pain in high-risk patients: the TARGET trial. A multi-site pragmatic cluster randomized trial. *eClinicalMedicine* 2021;34: 100795.
  21. Delitto A, Patterson CG, Stevans JM, et al. Study protocol for targeted interventions to prevent chronic low back pain in high-risk patients: a multi-site pragmatic cluster randomized controlled trial (TARGET Trial). *Contemp Clin Trials* 2019;82:66–76.
  22. Hill JC, Dunn KM, Lewis M, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. *Arthritis Rheum* 2008; 59:632–41.
  23. Deyo RA, Dworkin SF, Amtmann D, et al. Report of the NIH task force on research standards for chronic low back pain. *Spine (Phila Pa 1976)* 2014; 39:1128–43.
  24. Roland M, Fairbank J. The Roland-Morris Disability Questionnaire and the Oswestry Disability Questionnaire. *Spine (Phila Pa 1976)* 2000;25:3115–24.
  25. Li T. A unified view on clustering binary data. *Mach Learn* 2006;62:199–215.
  26. Kamper SJ, Logan G, Copsey B, et al. What is usual care for low back pain? A systematic review of health care provided to patients with low back pain in family practice and emergency departments. *Pain* 2020;161:694–702.
  27. Roseen EJ, Conyers FG, Atlas SJ, Mehta DH. Initial Management of acute and chronic low back pain: responses from brief interviews of primary care providers. *J Altern Complement Med* 2021;27: S106–S114.
  28. Mannion AF, Wieser S, Elfering A. Association between beliefs and care-seeking behavior for low back pain. *Spine (Phila Pa 1976)* 2013;38: 1016–25.

29. Hall A, Coombs D, Richmond H, et al. What do the general public believe about the causes, prognosis and best management strategies for low back pain? A cross-sectional study. *BMC Public Health* 2021;21:682–7.
30. Jenkins HJ, Kongsted A, French SD, et al. Patients with low back pain presenting for chiropractic care who want diagnostic imaging are more likely to receive referral for imaging: a cross-sectional study. *Chiropr Man Therap* 2022;30:16–9.
31. O’Keeffe M, Ferreira GE, Harris IA, et al. Effect of diagnostic labelling on management intentions for non-specific low back pain: a randomized scenario-based experiment. *Eur J Pain* 2022;26:1532–45.
32. Oliveira CB, Hamilton M, Traeger A, et al. Do patients with acute low back pain in emergency departments have more severe symptoms than those in general practice? A systematic review with meta-analysis. *Pain Med* 2022;23:614–24.
33. Rizzardo A, Miceli L, Bednarova R, Guadagnin GM, Sbrojavacca R, Rocca GD. Low-back pain at the emergency department: still not being managed? *Ther Clin Risk Manag* 2016;12:183–7.
34. Traeger AC, Machado GC, Bath S, et al. Appropriateness of imaging decisions for low back pain presenting to the emergency department: a retrospective chart review study. *Int J Qual Heal care J Int Soc Qual Heal Care* 2021;33.
35. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med* 2015;162:276–86.
36. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE Randomized Clinical Trial. *JAMA* 2018;319:872–82.
37. Middleton A, Fitzgerald GK, Delitto A, Saper RB, Gergen Barnett K, Stevans J. Implementing stratified care for acute low back pain in primary care using the STarT Back instrument: a process evaluation within the context of a large pragmatic cluster randomized trial. *BMC Musculoskelet Disord* 2020; 21:776–11.
38. Cherkin DC, Deyo RA, Goldberg H. Time to align coverage with evidence for treatment of back pain. *J Gen Intern Med* 2019;34:1910–2.
39. Fifer SK, Choudhry NK, Brod M, Hsu E, Milstein A. Improving adherence to guidelines for spine pain care: what tools could support primary care clinicians in conforming to guidelines? *BMJ open Qual* 2022;11.
40. Sharma S, Traeger AC, Tcharkhedian E, et al. “I would not go to him”: focus groups exploring community responses to a public health campaign aimed at reducing unnecessary diagnostic imaging of low back pain. *Health Expect* 2021; 24:648–58.

## Appendices.

### Appendix A

**Appendix Table A. Breakdown of Specific Medications Within Each Category**

| Category                              | Data for Each Category                               |
|---------------------------------------|--|
| Acetaminophen                         | Acetaminophen  |
| Acetaminophen                         | Tylenol  |
| Antidepressants                       | Amitriptyline  |
| Antidepressants                       | Bupropion HCL  |
| Antidepressants                       | Celexa   |
| Antidepressants                       | Citalopram   |
| Antidepressants                       | Clomipramine   |
| Antidepressants                       | Doxepin  |
| Antidepressants                       | Duloxetine   |
| Antidepressants                       | Escitalopram   |
| Antidepressants                       | Fluoxetine   |
| Antidepressants                       | Fluvoxamine  |
| Antidepressants                       | Mirtazapine  |
| Antidepressants                       | Nortriptyline  |
| Antidepressants                       | Olanzapine   |
| Antidepressants                       | Paroxetine   |
| Antidepressants                       | Perphenazine-amitriptyline                           |
| Antidepressants                       | Prozac   |
| Antidepressants                       | Quetiapine   |
| Antidepressants                       | Remeron  |
| Antidepressants                       | Trazodone  |
| Antidepressants                       | Venlafaxine  |
| Antidepressants                       | Zoloft   |
| Behavioral Health                     | Consult/Referral to Behavioral Health Program        |
| Behavioral Health                     | Consult/Referral to Neuropsychology                  |
| Behavioral Health                     | Consult/Referral to Psychiatry                       |
| Behavioral Health                     | Consult/Referral to Psychology                       |
| Behavioral Health                     | Consult/Referral to Psychology Evaluation            |
| BENZOS                                | Alprazolam   |
| BENZOS                                | Clonazepam   |
| BENZOS                                | Diazepam   |
| BENZOS                                | Klonopin   |
| BENZOS                                | lorazepam  |
| BENZOS                                | Oxazepam   |
| BENZOS                                | Temazepam  |
| BENZOS                                | Triazolam  |
| BENZOS                                | Valium   |
| Chiropractic/Osteopathic Manipulation | Consult/Referral to Chiropractic Therapy             |
| Chiropractic/Osteopathic Manipulation | Consult/Referral to Osteopathic Manipulative Therapy |
| Chiropractic/Osteopathic Manipulation | Osteopathic Manipulative Tx 1 to 2 Body Regions      |
| Chiropractic/Osteopathic Manipulation | Osteopathic Manipulative Tx 3 to 4 Body Regions      |
| Chiropractic/Osteopathic Manipulation | Osteopathic Manipulative Tx 5 to 6 Body Regions      |
| Chiropractic/Osteopathic Manipulation | Osteopathic Manipulative Tx 7 to 8 Body Regions      |
| Coaching/Wellness/Lifestyle           | Consult/Referral for Wellness Education              |

*Continued*

Appendix Table A. Continued

| Category                    | Data for Each Category                                     |
|-----------------------------|--|
| Coaching/Wellness/Lifestyle | Consult/Referral to Prescription for Wellness Health Coach |
| Diagnostic Imaging - MR/CT  | CT Lumbar spine  |
| Diagnostic Imaging - MR/CT  | CT Lumbar spine  |
| Diagnostic Imaging - MR/CT  | MR Lumbar and Thoracic spine                               |
| Diagnostic Imaging - MR/CT  | MR Lumbar spine  |
| Diagnostic Imaging - MR/CT  | MR Lumbo-sacral spine                                      |
| Diagnostic Imaging - XRAY   | Xray Lumbar Spine 2 or 3 views                             |
| Diagnostic Imaging - XRAY   | Xray Lumbar Spine Minimum 4 views                          |
| Diagnostic Imaging - XRAY   | XRay Lumbar Spine Minimum 4 views with Oblique             |
| Diagnostic Imaging - XRAY   | Xray Lumbar Spine with Flex and Ext.                       |
| Diagnostic Imaging - XRAY   | XRay pelvic complete minimum 3 views                       |
| Diagnostic Imaging - XRAY   | XRay Sacroiliac Joints (G)                                 |
| Diagnostic Imaging - XRAY   | XRay Sacroiliac Joints 1 or 2 Views                        |
| Diagnostic Imaging - XRAY   | XRay Sacroiliac Joints 3+ Views                            |
| Diagnostic Imaging - XRAY   | XRay Sacroiliac Joints less than 3 Views                   |
| Diagnostic Imaging - XRAY   | XRay Sacroiliac Joints Minimum 3 Views                     |
| Diagnostic Imaging - XRAY   | XRay Sacrum/Coccyx 2 Views                                 |
| Diagnostic Imaging - XRAY   | XRay Sacrum/Coccyx 2+ Views                                |
| Diagnostic Imaging - XRAY   | XRay Sacrum/Coccyx Minimum 2 Views                         |
| Diagnostic Imaging - XRAY   | XRay Spine Lumbar (G)                                      |
| Diagnostic Imaging - XRAY   | XRay Spine Lumbar 1 View                                   |
| Diagnostic Imaging - XRAY   | XRay Spine Lumbosacral 2 or 3 Views                        |
| Diagnostic Imaging - XRAY   | XRay Spine Lumbosacral 4+ Views                            |
| Diagnostic Imaging - XRAY   | XRay Spine Lumbosacral w/ Bending 6+ Views                 |
| Diagnostic Imaging - XRAY   | XRay Spine Scoliosis Study (G)                             |
| Diagnostic Imaging - XRAY   | XRay Spine Thoracolumbar 2 Views                           |
| Diagnostic Imaging - XRAY   | XRay Spine Thoracolumbar 2+ Views                          |
| Mind and Body Therapies     | Consult/Referral for Acupuncture                           |
| Mind and Body Therapies     | Consult/Referral for Musculoskeletal Health                |
| Mind and Body Therapies     | Consult/Referral Massage Therapy                           |
| Mind and Body Therapies     | Massage Therapy  |
| MUSCLE RELAXANT             | Baclofen   |
| MUSCLE RELAXANT             | Carisoprodol   |
| MUSCLE RELAXANT             | Chlorzoxazone  |
| MUSCLE RELAXANT             | Cyclobenzaprine  |
| MUSCLE RELAXANT             | Flexeril   |
| MUSCLE RELAXANT             | Metaxalone   |
| MUSCLE RELAXANT             | Methocarbamol  |
| MUSCLE RELAXANT             | Orphenadrine   |
| MUSCLE RELAXANT             | Tizanidine   |
| Neurology                   | Consult/Referral to Neurology                              |
| NSAIDS                      | Celecoxib  |
| NSAIDS                      | Diclofenac   |
| NSAIDS                      | Diclofenac-epolamine                                       |
| NSAIDS                      | Diflunisal   |
| NSAIDS                      | Etodolac   |
| NSAIDS                      | Flurbiprofen   |
| NSAIDS                      | Ibuprofen  |
| NSAIDS                      | Ibuprofen-famotidine                                       |

Continued



Appendix Table A. Continued

| Category                                  | Data for Each Category  |
|---|---|
| NSAIDS                                    | Indomethacin  |
| NSAIDS                                    | Ketorolac   |
| NSAIDS                                    | Meloxicam   |
| NSAIDS                                    | Motrin  |
| NSAIDS                                    | Nabumetone  |
| NSAIDS                                    | Naprosyn  |
| NSAIDS                                    | Naproxen  |
| NSAIDS                                    | Oxaprozin   |
| NSAIDS                                    | Piroxicam   |
| NSAIDS                                    | Sulindac  |
| NSAIDS                                    | Toradol   |
| NSAIDS-topical                            | Diclofenac cream  |
| NSAIDS-topical                            | Voltaren cream  |
| Opioids                                   | Acetaminophen-codeine   |
| Opioids                                   | Butabital-acetaminophen-caffeine-codeine  |
| Opioids                                   | Fentanyl  |
| Opioids                                   | Hydrocodone   |
| Opioids                                   | Hydrocodone-acetaminophen   |
| Opioids                                   | Hydromorphone   |
| Opioids                                   | Methadone   |
| Opioids                                   | Morphine  |
| Opioids                                   | Morphone  |
| Opioids                                   | Oxycodone   |
| Opioids                                   | Oxycodone-acetaminophen   |
| Opioids                                   | Oxymorphone   |
| Opioids                                   | Tramadol  |
| Opioids                                   | Tramadol HCL  |
| Opioids                                   | Tramadol-acetaminophen  |
| Opioids                                   | Vicodine  |
| Pain Management                           | Consult/Referral for Peti-Chronic Pain Treatment  |
| Pain Management                           | Consult/Referral to Pain Clinic   |
| Pain Management                           | Consult/Referral to Pain Management   |
| Pain Management                           | Consult/Referral to Physical Medicine and Rehabilitation                                    |
| Pain Management                           | Consult/Referral to Sports Medicine   |
| Physical Therapy/Rehabilitation           | Consult/Referral to Aqua Therapy  |
| Physical Therapy/Rehabilitation           | Consult/Referral to Flexibility Exercise  |
| Physical Therapy/Rehabilitation           | Consult/Referral to Physical Therapy  |
| Physical Therapy/Rehabilitation           | Physical Therapy (PT) Evaluation and Treatment  |
| Physical Therapy/Rehabilitation           | Physical Therapy (PT) Outpatient Evaluation and Treatment                                   |
| Psychologically Informed Physical Therapy | Consult/Referral to Psychologically Informed Physical Therapy (Stratified approach for LBP) |
| Social Work                               | Consult/Referral to Social Work   |
| Social Work                               | Consult/Referral to Social Work/Case Management   |
| Spine Surgery                             | Consult/Referral to Neurosurgery  |
| Spine Surgery                             | Consult/Referral to Neurosurgery spine  |
| Spine Surgery                             | Consult/Referral to Orthopedics   |
| Spine Surgery                             | Consult/Referral to Orthopedics-spine   |
| Steroids                                  | Dexamethasone   |
| Steroids                                  | Dexamethasone - injection   |
| Steroids                                  | Hydrocortisone  |

Continued

**Appendix Table A. Continued**

| Category | Data for Each Category                          |
|----------|---|
| Steroids | Medrol  |
| Steroids | Methylprednisolone                              |
| Steroids | Methylprednisolone acetate - injection          |
| Steroids | Methylprednisolone sodium succinate - injection |
| Steroids | Prednisone                                      |

*Abbreviations:* NSAID, non-steroidal anti-inflammatory drugs; MRI, magnetic resonance imaging; CT, computed tomography.

Appendix B

Appendix Table B. Comparison of Training Data and Validation Data Clusters in the 4-Cluster Model

|                            | Validation     |          | Training       |          | Validation                   |          | Training                     |          | Validation |         | Training |         | Validation |         | Training |           |
|----------------------------|----------------|----------|----------------|----------|------------------------------|----------|------------------------------|----------|------------|---------|----------|---------|------------|---------|----------|-----------|
|                            | 2nd Line Pharm | n = 1470 | 2nd Line Pharm | n = 1747 | Non-Pharm and 1st Line Pharm | n = 1810 | Non-Pharm and 1st Line Pharm | n = 1789 | Imaging    | n = 525 | Imaging  | n = 305 | Specialty  | n = 268 | Imaging  | Specialty |
| Female n, %                | 818            | 56%      | 985            | 56%      | 1063                         | 59%      | 1032                         | 58%      | 323        | 62%     | 196      | 64%     | 137        | 51%     | 125      | 54%       |
| Age mean, std              | 50             | 16       | 51             | 16       | 48                           | 17       | 49                           | 17       | 56         | 18      | 55       | 20      | 53         | 16      | 54       | 16        |
| Body Mass Index, mean      | 32             | 32       | 32             | 32       | 32                           | 32       | 32                           | 32       | 30         | 30      | 30       | 30      | 32         | 32      | 32       | 32        |
| Site                       |                |          |                |          |                              |          |                              |          |            |         |          |         |            |         |          |           |
| BMC                        | 50             | 3%       | 56             | 3%       | 332                          | 18%      | 293                          | 16%      | 12         | 2%      | 15       | 5%      | 36         | 113%    | 23       | 109%      |
| IMH                        | 406            | 28%      | 472            | 27%      | 347                          | 19%      | 335                          | 19%      | 81         | 15%     | 50       | 16%     | 53         | 20%     | 46       | 20%       |
| JHU                        | 162            | 11%      | 171            | 10%      | 395                          | 22%      | 411                          | 23%      | 62         | 12%     | 38       | 12%     | 56         | 21%     | 52       | 22%       |
| UPMC                       | 852            | 58%      | 1048           | 60%      | 736                          | 41%      | 750                          | 42%      | 370        | 70%     | 202      | 66%     | 124        | 47%     | 112      | 48%       |
| Anxiety or depression n, % | 141            | 10%      | 143            | 8%       | 72                           | 4%       | 67                           | 4%       | 30         | 6%      | 12       | 4%      | 19         | 7%      | 20       | 9%        |
| Obese n, %                 | 775            | 53%      | 908            | 52%      | 948                          | 52%      | 967                          | 54%      | 222        | 42%     | 118      | 39%     | 139        | 52%     | 133      | 57%       |
| Insurance                  |                |          |                |          |                              |          |                              |          |            |         |          |         |            |         |          |           |
| SelfPay/Other/Missing      | 263            | 18%      | 289            | 17%      | 442                          | 24%      | 408                          | 23%      | 90         | 17%     | 37       | 12%     | 61         | 23%     | 48       | 21%       |
| Medicaid                   | 132            | 9%       | 141            | 8%       | 188                          | 10%      | 186                          | 10%      | 37         | 7%      | 21       | 7%      | 24         | 9%      | 18       | 8%        |
| Medicare                   | 291            | 20%      | 326            | 19%      | 295                          | 16%      | 274                          | 15%      | 170        | 32%     | 93       | 31%     | 58         | 22%     | 61       | 26%       |
| private                    | 784            | 53%      | 991            | 57%      | 885                          | 49%      | 921                          | 51%      | 228        | 43%     | 153      | 50%     | 123        | 46%     | 105      | 45%       |
| Smoking status n, %        |                |          |                |          |                              |          |                              |          |            |         |          |         |            |         |          |           |
| Not current smoker         | 956            | 65%      | 1122           | 64%      | 1140                         | 63%      | 1098                         | 61%      | 391        | 74%     | 234      | 77%     | 156        | 59%     | 140      | 60%       |
| Current smoker             | 227            | 15%      | 275            | 16%      | 179                          | 10%      | 184                          | 10%      | 51         | 10%     | 22       | 7%      | 45         | 17%     | 27       | 12%       |
| Missing/unknown            | 287            | 20%      | 350            | 20%      | 491                          | 27%      | 507                          | 28%      | 83         | 16%     | 48       | 16%     | 65         | 24%     | 65       | 28%       |
| Race n, %                  |                |          |                |          |                              |          |                              |          |            |         |          |         |            |         |          |           |
| White                      | 1289           | 88%      | 1556           | 89%      | 1250                         | 69%      | 1264                         | 71%      | 454        | 86%     | 257      | 85%     | 210        | 79%     | 194      | 84%       |
| Black                      | 113            | 8%       | 116            | 7%       | 389                          | 21%      | 374                          | 21%      | 45         | 9%      | 32       | 11%     | 37         | 14%     | 25       | 11%       |
| Missing                    | 32             | 2%       | 37             | 2%       | 75                           | 4%       | 81                           | 5%       | 12         | 2%      | 6        | 2%      | 8          | 3%      | 4        | 2%        |
| Other                      | 36             | 2%       | 38             | 2%       | 96                           | 5%       | 70                           | 4%       | 14         | 3%      | 9        | 3%      | 11         | 4%      | 9        | 4%        |
| Hispanic n, %              |                |          |                |          |                              |          |                              |          |            |         |          |         |            |         |          |           |
| Non-Hispanic               | 1397           | 95%      | 1652           | 95%      | 1658                         | 92%      | 1612                         | 90%      | 499        | 95%     | 284      | 93%     | 242        | 91%     | 214      | 92%       |
| Hispanic                   | 43             | 3%       | 44             | 3%       | 102                          | 6%       | 102                          | 6%       | 15         | 3%      | 9        | 3%      | 15         | 6%      | 10       | 4%        |
| Missing                    | 30             | 2%       | 51             | 3%       | 50                           | 3%       | 75                           | 4%       | 11         | 2%      | 11       | 4%      | 9          | 3%      | 8        | 3%        |

Continued

Appendix Table B. Continued

|                          | Validation     | Training       | Validation                   | Training                     | Validation | Training | Validation | Training  |
|--------------------------|----------------|----------------|------------------------------|------------------------------|------------|----------|------------|-----------|
|                          | 2nd Line Pharm | 2nd Line Pharm | Non-Pharm and 1st Line Pharm | Non-Pharm and 1st Line Pharm | Imaging    | Imaging  | Specialty  | Specialty |
|                          | n = 1470       | n = 1747       | n = 1810                     | n = 1789                     | n = 525    | n = 305  | n = 268    | n = 232   |
| Back pain diagnosis n, % |                |                |                              |                              |            |          |            |           |
| Axial back pain          | 999            | 1118           | 1472                         | 1452                         | 356        | 225      | 156        | 123       |
| Back and leg             | 471            | 629            | 338                          | 337                          | 169        | 79       | 110        | 109       |
| Duration of LBP n, %     |                |                |                              |                              |            |          |            |           |
| Less than 1 month        | 996            | 1188           | 1147                         | 1115                         | 280        | 143      | 117        | 113       |
| 1 to 3 months            | 282            | 365            | 424                          | 441                          | 157        | 101      | 89         | 77        |
| More than 3 months       | 192            | 194            | 239                          | 233                          | 88         | 60       | 60         | 42        |
| STarT Back Category      |                |                |                              |                              |            |          |            |           |
| High                     | 424            | 482            | 441                          | 388                          | 141        | 44       | 102        | 94        |
| Low                      | 359            | 441            | 686                          | 702                          | 188        | 141      | 59         | 50        |
| Medium                   | 687            | 824            | 683                          | 699                          | 196        | 119      | 105        | 88        |
| Chronic at 6 months n, % | 328/888        | 343/1034       | 267/966                      | 240/893                      | 110/295    | 42/170   | 87/151     | 53/120    |
| ODI Baseline n, mean     | 1426           | 1698           | 1749                         | 1737                         | 515        | 298      | 260        | 229       |
| ODI 6 Months n, mean     | 891            | 1034           | 973                          | 899                          | 298        | 172      | 151        | 121       |
|                          |                |                |                              |                              |            |          |            |           |
| CLUSTER                  |                |                |                              |                              |            |          |            |           |
|                          | Validation     | Training       | Validation                   | Training                     | Validation | Training | Validation | Training  |
|                          | 2nd Line Pharm | 2nd Line Pharm | Non-Pharm and 1st Line Pharm | Non-Pharm and 1st Line Pharm | Imaging    | Imaging  | Specialty  | Specialty |
|                          | n = 1470       | n = 1747       | n = 1810                     | n = 1789                     | n = 525    | n = 305  | n = 268    | n = 232   |
| Non-Pharm                | 494            | 591            | 962                          | 901                          | 209        | 117      | 42         | 40        |
| Pharm1                   | 889            | 948            | 1430                         | 1438                         | 0          | 0        | 116        | 85        |
| Pharm2                   | 1470           | 1747           | 0                            | 12                           | 206        | 0        | 154        | 141       |
| Specialty                | 0              | 0              | 39                           | 69                           | 14         | 7        | 268        | 232       |
| Imaging                  | 255            | 460            | 264                          | 266                          | 525        | 305      | 88         | 75        |

Abbreviations: BMC, Boston medical center; IMH, Institute of mental health; UPMC, University of Pittsburgh medical center; JHU, Johns Hopkins university.